Spiramycin, like erythromycin, belongs to the macrolide class of antibiotics, both of which inhibit bacterial growth by inhibiting bacterial protein synthesis and belong to a relatively narrow antibacterial range, i.e., narrow-spectrum antibacterial agents. Clinical spiramycin can be used to treat mild and moderate infections caused by sensitive bacteria, mainly Staphylococcus, Streptococcus spp. and Streptococcus pneumoniae, such as upper respiratory tract infections, such as pharyngitis and tonsillitis; lower respiratory tract infections, such as acute tracheobronchitis, acute attacks of chronic bronchitis, pneumonia, etc. Infections of the five senses, such as sinusitis, otitis media, periodontitis, etc.; skin soft tissue infections and urethritis caused by non-gonococci. In addition, spiramycin can also treat other diseases such as Cryptosporidium toxoplasmosis.